Trinity Meds is an online weight-management platform connecting adults with licensed clinicians
Glutathione Precursor: Supplies L-cysteine, the limiting amino acid in glutathione production
For individuals who do not qualify for GLP-1 therapies or who need support in behavioral patterns rather than hunger alone, Contrave provides a reliable and clinically meaningful path toward improvement
Severe or multisystem metabolic disease: Significant obesity plus diabetes, MASLD, OSA, or clustered cardiovascular risk factors, where every extra few percentage points of weight and risk reduction matter. Patients who need maximum, not moderate, change: Those aiming for 20%plus loss to qualify for surgery, offload joints, or defuse highstakes diagnoses in a defined time window. Patients who can handle tighter structure: People willing to tolerate stronger appetite suppression, closer titration, and more lab and nutrition oversight in exchange for bigger, faster shifts in body weight and cardiometabolic markers. Who leans toward semaglutide
More commonly tied to cagrilintide than tirzepatide
It will determine whether retatrutide produces a reduction in major adverse cardiovascular events (MACE) comparable to or greater than the SELECT trial result for semaglutide (20% reduction)